Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Current Deferred Revenue: 2021-2024

  • ProQR Therapeutics N.V's Current Deferred Revenue rose 5.95% to $23.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $23.4 million, marking a year-over-year increase of 5.95%. This contributed to the annual value of $23.4 million for FY2024, which is 5.38% up from last year.
  • Per ProQR Therapeutics N.V's latest filing, its Current Deferred Revenue stood at $23.4 million for Q4 2024, which was up 5.95% from $22.1 million recorded in Q4 2023.
  • In the past 5 years, ProQR Therapeutics N.V's Current Deferred Revenue ranged from a high of $23.4 million in Q4 2024 and a low of $2.5 million during Q3 2021.
  • Its 3-year average for Current Deferred Revenue is $17.1 million, with a median of $22.1 million in 2023.
  • As far as peak fluctuations go, ProQR Therapeutics N.V's Current Deferred Revenue decreased by 1.64% in 2022, and later surged by 284.54% in 2023.
  • ProQR Therapeutics N.V's Current Deferred Revenue (Quarterly) stood at $5.9 million in 2021, then dropped by 1.64% to $5.8 million in 2022, then spiked by 284.54% to $22.1 million in 2023, then rose by 5.95% to $23.4 million in 2024.
  • Its Current Deferred Revenue was $23.4 million in Q4 2024, compared to $22.1 million in Q4 2023 and $5.8 million in Q4 2022.